Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07336940 · ClinicalTrials.gov registry record · Phase 1

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 1 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.

Active
Registry status
Phase 1
Development phase
16
Enrollment target
5
Study locations

NCT07336940 is a Phase 1 study of Atopic Dermatitis (AD) that is active but no longer recruiting, run by Enveda Therapeutics. The registered enrollment target is 16 participants, below the 108-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07336940, a Phase 1 study of Atopic Dermatitis (AD), is active but no longer recruiting, sponsored by Enveda Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target
5
Study locations

Study Summary

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis? * Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 once every day for 28 days * Visit the clinic weekly for 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294

Conditions Studied

Atopic Dermatitis (AD)

Interventions

  • DRUG ENV-294 Capsule

Study Locations (5)

Texas

  • J & S Studies - College Station
  • Texas Dermatology and Laser Specialists - San Antonio

California

  • Center for Dermatology Clinical Research, Inc. - Fremont

Kentucky

  • Skin Sciences, PLLC - Louisville

Virginia

  • Virginia Dermatology & Skin Cancer Center - Norfolk

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-09-10
Est. Completion 2026-03
Phase Phase 1

Sponsor

Enveda Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07336940

The ClinicalTrials.gov registry entry for NCT07336940 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (85% lower). The listed sponsor is Enveda Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 1 intervention - of which ENV-294 Capsule is the first listed.

NCT07336940 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT07336940 about?

NCT07336940 is a clinical study titled "Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis". The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe...

What is the current status of trial NCT07336940?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-09-10. Estimated completion is 2026-03.

What conditions does trial NCT07336940 study?

This clinical trial studies the following conditions: Atopic Dermatitis (AD).

What interventions are being tested in trial NCT07336940?

The interventions under investigation include: ENV-294 Capsule (DRUG).

Who is sponsoring clinical trial NCT07336940?

This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07336940 being conducted?

This trial has 5 study locations across California, Kentucky, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis (AD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis (AD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.